Evolus (EOLS) Stock: Buy, Sell, or Hold?
EOLS - Evolus, Inc. Common Stock
$7.14
-0.55 (-7.15%)
▼
5d:
-10.41%
30d:
-21.19%
90d:
+2.15%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When EOLS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: EOLS is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: EOLS is down 10.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$10.25
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$6.36
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: EOLS is currently trading at $7.14, which is considered oversold relative to its 30-day fair value range of $7.78 to $8.89. From a valuation perspective, the stock is trading at a discount (Forward PE: 24.4) compared to its historical average (29.1). Remarkably, the market is currently pricing in an annual earnings decline of 5.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, EOLS is in a strong downtrend. Immediate support is located at $6.91, while resistance sits at $8.51. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: EOLS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+110.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EOLS is in a strong downtrend. Immediate support is located at $6.91, while resistance sits at $8.51. Short-term momentum is weak, with the stock down 7.2% recently.
Market Sentiment: EOLS scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $15.00 (+110.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$7.78 -
$8.89
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.4%
Protect Your Profits
Holding EOLS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-7.2%)
- BULLISH: Trading 110.1% below Wall St target ($15.00)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.78 -
$8.89
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$6.91
Resistance Level
$8.51
Current Trend
Strong Downtrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
24.41
Wall Street Target
$15.00
(+110.1%)
Revenue Growth (YoY)
21.2%
Profit Margin
-10.8%
Valuation Discount vs History
-5.7% cheaper
PE vs Historical
24.4 vs 29.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-5.7%
(market-implied from PE analysis)
1-Year Target
$6.73
(-6%)
2-Year Target
$6.35
(-11%)
3-Year Target
$5.99
(-16%)
3-Yr Target (if PE normalizes)
(PE: 24→29)
$7.14
(0%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 24.4 to 29.1
Stabilization Target:
$8.51
(+19.2%)
PE Expansion Potential:
+19.2%
Share & Embed Analysis
Last updated: October 03, 2026 1:52 AM ET
Data refreshes hourly during market hours. Next update: 2:52 AM
Data refreshes hourly during market hours. Next update: 2:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EOLS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
Advanced EOLS Option Strategies
Professional options setups generated by AI based on today's EOLS price and gamma walls.
